These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Prediction of Sanfilippo phenotype severity from immunoquantification of heparan-N-sulfamidase in cultured fibroblasts from mucopolysaccharidosis type IIIA patients. Perkins KJ; Muller V; Weber B; Hopwood JJ Mol Genet Metab; 2001 Aug; 73(4):306-12. PubMed ID: 11509012 [TBL] [Abstract][Full Text] [Related]
44. Evaluation of heparin cofactor II-thrombin complex as a biomarker on blood spots from mucopolysaccharidosis I, IIIA and IIIB mice. Langford-Smith K; Arasaradnam M; Wraith JE; Wynn R; Bigger BW Mol Genet Metab; 2010 Mar; 99(3):269-74. PubMed ID: 19926322 [TBL] [Abstract][Full Text] [Related]
45. Serum global metabolomics profiling reveals profound metabolic impairments in patients with MPS IIIA and MPS IIIB. Fu H; Meadows AS; Pineda RJ; Mohney RP; Stirdivant S; McCarty DM Metab Brain Dis; 2017 Oct; 32(5):1403-1415. PubMed ID: 28382573 [TBL] [Abstract][Full Text] [Related]
46. Systemic scAAV9.U1a.hSGSH Delivery Corrects Brain Biochemistry in Mucopolysaccharidosis Type IIIA at Early and Later Stages of Disease. Saville JT; Derrick-Roberts ALK; McIntyre C; Fuller M Hum Gene Ther; 2021 Apr; 32(7-8):420-430. PubMed ID: 33339477 [TBL] [Abstract][Full Text] [Related]
47. Systemic immune challenge exacerbates neurodegeneration in a model of neurological lysosomal disease. Mandolfo O; Parker H; Aguado È; Ishikawa Learmonth Y; Liao AY; O'Leary C; Ellison S; Forte G; Taylor J; Wood S; Searle R; Holley RJ; Boutin H; Bigger BW EMBO Mol Med; 2024 Jul; 16(7):1579-1602. PubMed ID: 38890537 [TBL] [Abstract][Full Text] [Related]
48. Sulfamidase deficiency in a family of Dachshunds: a canine model of mucopolysaccharidosis IIIA (Sanfilippo A). Fischer A; Carmichael KP; Munnell JF; Jhabvala P; Thompson JN; Matalon R; Jezyk PF; Wang P; Giger U Pediatr Res; 1998 Jul; 44(1):74-82. PubMed ID: 9667374 [TBL] [Abstract][Full Text] [Related]
49. Early disease course is unaltered in mucopolysaccharidosis type IIIA (MPS IIIA) mice lacking α-synuclein. Soe K; Beard H; Neumann D; Trim PJ; Duplock S; Snel MF; Hopwood JJ; Hemsley KM Neuropathol Appl Neurobiol; 2019 Dec; 45(7):715-731. PubMed ID: 30907009 [TBL] [Abstract][Full Text] [Related]
51. Slow, continuous enzyme replacement via spinal CSF in dogs with the paediatric-onset neurodegenerative disease, MPS IIIA. King B; Marshall NR; Hassiotis S; Trim PJ; Tucker J; Hattersley K; Snel MF; Jolly RD; Hopwood JJ; Hemsley KM J Inherit Metab Dis; 2017 May; 40(3):443-453. PubMed ID: 27832416 [TBL] [Abstract][Full Text] [Related]
52. Trans-generational exposure to low levels of rhodamine B does not adversely affect litter size or liver function in murine mucopolysaccharidosis type IIIA. Roberts AL; Fletcher JM; Moore L; Byers S Mol Genet Metab; 2010; 101(2-3):208-13. PubMed ID: 20650670 [TBL] [Abstract][Full Text] [Related]
53. Development of cerebellar pathology in the canine model of mucopolysaccharidosis type IIIA (MPS IIIA). Hassiotis S; Jolly RD; Hemsley KM Mol Genet Metab; 2014 Dec; 113(4):283-93. PubMed ID: 25453402 [TBL] [Abstract][Full Text] [Related]
54. Intracerebroventricular dosing of N-sulfoglucosamine sulfohydrolase in mucopolysaccharidosis IIIA mice reduces markers of brain lysosomal dysfunction. Magat J; Jones S; Baridon B; Agrawal V; Wong H; Giaramita A; Mangini L; Handyside B; Vitelli C; Parker M; Yeung N; Zhou Y; Pungor E; Slabodkin I; Gorostiza O; Aguilera A; Lo MJ; Alcozie S; Christianson TM; Tiger PMN; Vincelette J; Fong S; Gil G; Hague C; Lawrence R; Wendt DJ; Lebowitz JH; Bunting S; Bullens S; Crawford BE; Roy SM; Woloszynek JC J Biol Chem; 2022 Dec; 298(12):102625. PubMed ID: 36306823 [TBL] [Abstract][Full Text] [Related]
55. Impairment of glycosaminoglycan synthesis in mucopolysaccharidosis type IIIA cells by using siRNA: a potential therapeutic approach for Sanfilippo disease. Dziedzic D; Wegrzyn G; Jakóbkiewicz-Banecka J Eur J Hum Genet; 2010 Feb; 18(2):200-5. PubMed ID: 19690584 [TBL] [Abstract][Full Text] [Related]
56. An Engineered Douek AM; Amiri Khabooshan M; Henry J; Stamatis SA; Kreuder F; Ramm G; Änkö ML; Wlodkowic D; Kaslin J Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073041 [TBL] [Abstract][Full Text] [Related]
58. Continual Low-Dose Infusion of Sulfamidase Is Superior to Intermittent High-Dose Delivery in Ameliorating Neuropathology in the MPS IIIA Mouse Brain. Beard H; Hassiotis S; Luck AJ; Rozaklis T; Hopwood JJ; Hemsley KM JIMD Rep; 2016; 29():59-68. PubMed ID: 26620043 [TBL] [Abstract][Full Text] [Related]
59. Allogeneic stem cell transplantation does not improve neurological deficits in mucopolysaccharidosis type IIIA mice. Lau AA; Hannouche H; Rozaklis T; Hassiotis S; Hopwood JJ; Hemsley KM Exp Neurol; 2010 Oct; 225(2):445-54. PubMed ID: 20673764 [TBL] [Abstract][Full Text] [Related]
60. Neurodevelopmental Changes in Excitatory Synaptic Structure and Function in the Cerebral Cortex of Sanfilippo Syndrome IIIA Mice. Dwyer CA; Scudder SL; Lin Y; Dozier LE; Phan D; Allen NJ; Patrick GN; Esko JD Sci Rep; 2017 Apr; 7():46576. PubMed ID: 28418018 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]